⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15319504 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL15319954 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL15319952 | 0.97 | — | — | |
| SCHEMBL22783114 | 0.79 | — | — | |
| SCHEMBL10379518 | 0.77 | — | — | |
| SCHEMBL16511402 | 0.72 | — | — | |
| SCHEMBL15276753 | 0.67 | — | — | |
| SCHEMBL17669225 | 0.65 | — | — | |
| SCHEMBL25403501 | 0.65 | — | — | |
| SCHEMBL25403084 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2834239-B1 | HETEROBICYCLIC COMPOUNDS AS BETA-LACTAMASE INHIBITORS | ENTASIS THERAPEUTICS LTD (GB) | 2017-12-27 | — | — | EP | disclosed |
| EP-2834239-B1 | HETEROBICYCLIC COMPOUNDS AS BETA-LACTAMASE INHIBITORS | ENTASIS THERAPEUTICS LTD (GB) | 2017-12-27 | — | — | EP | disclosed |
| US-9623014-B2 | β-lactamase inhibitor compounds | ENTASIS THERAPEUTICS LIMITED (GB) | 2017-04-18 | — | — | US | disclosed |
| US-9623014-B2 | β-lactamase inhibitor compounds | ENTASIS THERAPEUTICS LIMITED (GB) | 2017-04-18 | — | — | US | disclosed |
| US-9623014-B2 | β-lactamase inhibitor compounds | ENTASIS THERAPEUTICS LIMITED (GB) | 2017-04-18 | — | — | US | disclosed |
| US-20160175290-A1 | BETA-LACTAMASE INHIBITOR COMPOUNDS | ASTRAZENECA PHARMACEUTICALS LP | 2016-06-23 | — | — | US | disclosed |
| US-20160175290-A1 | BETA-LACTAMASE INHIBITOR COMPOUNDS | ASTRAZENECA PHARMACEUTICALS LP | 2016-06-23 | — | — | US | disclosed |
| US-20160175290-A1 | BETA-LACTAMASE INHIBITOR COMPOUNDS | ASTRAZENECA PHARMACEUTICALS LP | 2016-06-23 | — | — | US | disclosed |
| US-9309245-B2 | Beta-lactamase inhibitor compounds | ENTASIS THERAPEUTICS LIMITED (GB) | 2016-04-12 | — | — | US | disclosed |
| US-9309245-B2 | Beta-lactamase inhibitor compounds | ENTASIS THERAPEUTICS LIMITED (GB) | 2016-04-12 | — | — | US | disclosed |
| US-9309245-B2 | Beta-lactamase inhibitor compounds | ENTASIS THERAPEUTICS LIMITED (GB) | 2016-04-12 | — | — | US | disclosed |
| US-20150073011-A1 | Beta-Lactamase Inhibitor Compounds | ASTRAZENECA AB (SE) | 2015-03-12 | — | — | US | disclosed |
| US-20150073011-A1 | Beta-Lactamase Inhibitor Compounds | ASTRAZENECA AB (SE) | 2015-03-12 | — | — | US | disclosed |
| US-20150073011-A1 | Beta-Lactamase Inhibitor Compounds | ASTRAZENECA AB (SE) | 2015-03-12 | — | — | US | disclosed |
| EP-2834239-A1 | HETEROBICYCLIC COMPOUNDS AS BETA-LACTAMASE INHIBITORS | Astrazeneca AB (SE) | 2015-02-11 | — | — | EP | disclosed |
| WO-2013150296-A1 | HETEROBICYCLIC COMPOUNDS AS BETA-LACTAMASE INHIBITORS | ASTRAZENECA AB (SE) | 2013-10-10 | — | — | WO | disclosed |
| WO-2013150296-A1 | HETEROBICYCLIC COMPOUNDS AS BETA-LACTAMASE INHIBITORS | ASTRAZENECA AB (SE) | 2013-10-10 | — | — | WO | disclosed |